Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients

Shimizu, Hideo; Horimoto, Yoshiya; Arakawa, Atsushi; Sonoue, Hiroshi; Kurata, Morito; Kosaka, Taijiro; Nakai, Keiichi; Himuro, Takanori; Tokuda, Emi; Takahashi, Yuka; M, Ito; Abe, Ikuro; Senuma, Koji; Stork‐Sloots, Lisette; F, de Snoo; Saito, Mitsue

doi:10.1159/000376562

Cited by 6 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the long-term prognostic significance of the 21-gene RS has not been evaluated in Japanese patients. Moreover, the 70-gene MammaPrint assay has been tested in Japanese women with early breast cancer, but its prognostic value is unclear [ 26 , 27 ]. The multigene assay, Curebest 95GC Breast (Sysmex Corporation, Kobe, Japan), which measures the expression of 95 genes using DNA microarray, was developed in Japan [ 28 ] and is available for research purposes.…”

Section: Discussionmentioning

confidence: 99%

Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer

Fujiki,

Kashiwaba,

Sato

et al. 2023

Breast Cancer

View full text Add to dashboard Cite

Background Accurate prediction of the risk of recurrence is crucial for optimal treatment decisions in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. The GenesWell BCT is a molecular assay to predict the 10-year risk of distant metastasis. In this study, we evaluated the long-term prognostic value of the GenesWell BCT assay. Methods The BCT score was assessed in patients with HR-positive/HER2-negative early breast cancer who did not receive chemotherapy. We compared the 15-year distant metastasis-free survival (DMFS) between risk groups classified based on the BCT score. The risk of early (0–5 years) and late (5–15 years) recurrence was evaluated based on the BCT score classification. Results According to the BCT score, 366 patients from Japan and Korea were categorized as BCT low risk (83.6%) and high risk (16.4%) for distant metastasis. Median follow-up time was 17.4 years. The 15-year DMFS rate was significantly lower in the BCT high-risk group (63.3%) than in the BCT low-risk group (93.6%) (P < 0.001). The BCT risk group was an independent prognostic factor for 15-year DMFS (hazard ratio, 4.59; 95% confidence interval 2.13–9.88; P < 0.001). Furthermore, the BCT score was a significant predictor of late recurrence (5–15 years) in patients aged ≤ 50 years and those aged > 50 years, and added prognostic information to traditional clinical prognostic factors. Conclusion The BCT score can identify patients at low risk for recurrence who may not require adjuvant chemotherapy or extended endocrine therapy, regardless of age.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer

Fujiki,

Kashiwaba,

Sato

et al. 2023

Breast Cancer

View full text Add to dashboard Cite

show abstract

“…Numerous studies have published utility scores for health states related to PC assessed using various methods [33–38]. We chose the utility scores estimated by Stewart et al [37] on a sample of patients aged 60 (the mean/median patient age in the included study in our meta-analysis centered around this value, Table 3) and over.…”

Section: Methodsmentioning

confidence: 99%

Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)

Lorent

Maalmi

Tessier

et al. 2019

BMC Med Inform Decis Mak

View full text Add to dashboard Cite

BackgroundThe Cancer of the Prostate Risk Assessment (CAPRA) score was designed and validated several times to predict the biochemical recurrence-free survival after a radical prostatectomy. Our objectives were, first, to study the clinical validity of the CAPRA score, and, second, to assess its clinical utility for stratified medicine from an original patient-centered approach.MethodsWe proposed a meta-analysis based on a literature search using MEDLINE. Observed and predicted biochemical-recurrence-free survivals were compared to assess the calibration of the CAPRA score. Discriminative capacities were evaluated by estimating the summary time-dependent ROC curve. The clinical utility of the CAPRA score was evaluated according to the following stratified decisions: active monitoring for low-risk patients, prostatectomy for intermediate-risk patients, or radio-hormonal therapy for high risk patients. For this purpose, we assessed CAPRA’s clinical utility in terms of its ability to maximize time-dependent utility functions (i.e. Quality-Adjusted Life-Years – QALYs).ResultsWe identified 683 manuscripts and finally retained 9 studies. We reported good discriminative capacities with an area under the SROCt curve at 0.73 [95%CI from 0.67 to 0.79], while graphical calibration seemed acceptable. Nevertheless, we also described that the CAPRA score was unable to discriminate between the three medical alternatives, i.e. it did not allow an increase in the number of life years in perfect health (QALYs) of patients with prostate cancer.ConclusionsWe confirmed the prognostic capacities of the CAPRA score. In contrast, we were not able to demonstrate its clinical usefulness for stratified medicine from a patient-centered perspective. Our results also highlighted the confusion between clinical validity and utility. This distinction should be better considered in order to develop predictive tools useful in practice.Electronic supplementary materialThe online version of this article (10.1186/s12911-018-0727-2) contains supplementary material, which is available to authorized users.

show abstract

“…Our major research interest is to develop prognostic and predictive factors for breast cancer; for example, the application of a 70-gene expression profile to Japanese breast cancer patients is our recent work 14) .…”

Section: ) Hideo Shimizu (Assistant Professor)mentioning

confidence: 99%

Department of Breast and Endocrine Surgery (Breast Center)

2015

Juntendo Medical Journal

View full text Add to dashboard Cite

, and the development of a QOL questionnaire, as well as the management of multidisciplinary medical teams 1) 16) -18) . Group Leaders and Research Topics 1) Katsuya Nakai (Associate Professor)My research is focused on triple-negative breast cancer (TNBC). TNBC has a poor prognosis and has few treatment options. Therefore, a new treatment strategy is strongly desired. I have been working on the drug resistance and methylation of the DNA in TNBC. I am investigating epigenetic mechanisms such as histone modifications 6) 7) . 2) Yoshiya Horimoto (Associate Professor) I have dedicated myself to doing real translational research 8)-11). My personal research themes are: 1. how in situ nests of breast cancer achieve invasion through an interaction with stroma and 2. cancer cell dormancy induced by endocrine therapy. 3) Masahiko Tanabe (Associate Professor)The epidemiology of breast cancer is well known, but the molecular mechanism that connects epidemiology and biology associated with the carcinogenesis of breast cancer has not been revealed at all. I am engaged in studies on epigenetic change for breast cancer dependent on stimulation with estrogen. In addition, MMC/MTX treatment for metastatic breast cancer is among my interests for clinical work 12) . 4) Hideo Shimizu (Assistant Professor)Our major research interest is to develop prognostic and predictive factors for breast cancer; for example, the application of a 70-gene expression profile to Japanese breast cancer patients is our recent work 14) . 5) Emiko Tokuda (Assistant Professor)Our major research interest is to clarify the mechanism of the crosstalk between ER and HER2 signaling pathway, and we hope to achieve breakthroughs regarding the mechanism of drug resistance related to such crosstalk 13) .

show abstract

Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients

Cited by 6 publications

References 26 publications

Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer

Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer

Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)

Department of Breast and Endocrine Surgery (Breast Center)

Contact Info

Product

Resources

About